Evidence map›Paper›PMID 38658404›Full record

ArticleArchives of toxicology2024

In vitro to in vivo extrapolation to derive a metabolism factor for estimating the aggregate exposure to salicylic acid after dermal exposure of its esters.

Abdulkarim Najjar, Sebastien Grégoire, Beate Nicol, Andreas Natsch, Nazanin Golbamaki, Fanny Boisleve, Amaia Irizar, Brian Wall, Angus Swinscoe, Valérie Masini-Etévé and 5 more

Abstract read
In one paragraph

Article in Archives of toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Abdulkarim NajjarBeiersdorf AG, Beiersdorfstr. 1-9, 20245, Hamburg, Germany. Abdulkarim.Najjar@Beiersdorf.com.ORCID 0000-0003-4620-9830
Sebastien GrégoireL'Oreal Research & Innovation, Aulnay-Sous-Bois, France.
Beate NicolSafety and Environmental Assurance Centre, Unilever UK, Colworth Science Park, MK44 1LQ, Sharnbrook, United Kingdom.
Andreas NatschGivaudan Schweiz AG, CH-8310, Kemptthal, Switzerland.
Nazanin GolbamakiL'Oreal Research & Innovation, Aulnay-Sous-Bois, France.
Fanny BoisleveChanel, Neuilly, France.
Amaia IrizarThe International Fragrance Association (IFRA), Geneva, Switzerland.
Brian WallColgate-Palmolive Company, Piscataway, NJ, 08854, USA.
Angus SwinscoeWhitman Laboratories, The Estée Lauder Companies, Petersfield, United Kingdom.
Valérie Masini-EtévéL'Oréal Recherche & Innovation, Clichy, France.
Dan SelechnikResearch Institute for Fragrance Materials (RIFM), Inc., Woodcliff Lake, NJ, USA.
Anne Marie ApiResearch Institute for Fragrance Materials (RIFM), Inc., Woodcliff Lake, NJ, USA.
Peter GriemSymrise AG, Holzminden, Germany.
Nicola HewittSWS, Erzhausen, Germany.
Estefania CardamoneCosmetics Europe, Brussels, Belgium.

Funding

Cosmetics Europe No ID numberIFRA No ID numberRIFM No ID number
6 · The paper itself

Abstract

As part of the safety assessment of salicylate esters in cosmetics, we developed a metabolism factor based on in vitro to in vivo extrapolation (IVIVE) to provide a better estimation of the aggregate internal exposure to the common metabolite, salicylic acid. Optimal incubation conditions using human liver S9 were identified before measuring salicylic acid formation from 31 substances. Four control substances, not defined as salicylic esters but which could be mistaken as such due to their nomenclature, did not form salicylic acid. For the remaining substances, higher in vitro intrinsic clearance (CL

Indexed as

EstersSalicylic AcidAdministration, CutaneousComputer SimulationCosmeticsHalf-LifeHumansLiverModels, BiologicalSkinSkin AbsorptionCosmeticsEstersSalicylic AcidHigh-throughput pharmacokinetic modellingIVIVEMetabolism factorSafety assessmentSalicylate estersSalicylic acid

Identifiers

PMID38658404
PMCPMC11169020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.